Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

0.8690 UNCHANGED
Streaming Delayed Price Updated: 3:57 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 0.8690
Bid (Size) 0.8688 (1)
Ask (Size) 0.8900 (2)
Prev. Close 0.8690
Today's Range 0.8690 - 0.8690
52wk Range 0.8500 - 6.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023
MYNZ stock results show that Mainz Biomed beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-25.73%
-25.73%
1 Month
-15.63%
-15.63%
3 Month
-17.24%
-17.24%
6 Month
-59.95%
-59.95%
1 Year
-77.60%
-77.60%

More News

Read More
Mainz Biomed Reports Full Year 2023 Financial Results
From Mainz BioMed NV
Via GlobeNewswire
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Via Benzinga
Exposures COVID-19
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
From Mainz BioMed NV
Via GlobeNewswire
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
Via Benzinga
Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community
From Mainz BioMed NV
Via GlobeNewswire
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
From Mainz BioMed NV
Via GlobeNewswire
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
Via Benzinga
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
From Mainz BioMed NV
Via GlobeNewswire
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
Via News Direct
Topics Death
Exposures Death
Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle
Via Benzinga
Exposures COVID-19
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
Via Benzinga
Topics Death
Exposures Death
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
From Mainz BioMed NV
Via GlobeNewswire
2024 Marks a New Era Of Pharmaceutical Innovation
Via Benzinga
Exposures COVID-19
Mainz Biomed Provides Year-End Corporate Review 2023
From Mainz BioMed NV
Via GlobeNewswire
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
Via Benzinga
Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study
Via Benzinga
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
From Mainz BioMed NV
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.